FOLH1 and prostate cancer: In a retrospective analysis of 257 RCC patients, includingclearcell, papillary, and chromophobe subtypes, Spatz et al. reported that stronger PSMA expression correlatedwith higher tumor grade, more advanced stage, and worse overall survival.Furthermore, 18F-DCFPyL, a PSMA-targeted PET tracer usedin prostate cancer, demonstrated higher sensitivity for small lesiondetection and greater uptake in metastatic RCC compared with 18F-FDG in head-to-head studies.,